Molecular typing is based on molecular genetic screening and isn't yet routinely offered. Molecular subtypes and immunohistochemical surrogate markers in the tumors (HR, HER2, triple destructive) correlate in about 70%. The differentiation of luminal A and B subtypes by HR status and proliferation markers like Ki-67 can be helpful, https://johnniei318dls5.blogadvize.com/profile